Selected research
Market Structure
Global Mesalazine Suppositories Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Mesalazine Suppositories market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Mesalazine Suppositories is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Mesalazine Suppositories is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mesalazine Suppositories is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Mesalazine Suppositories is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mesalazine Suppositories include Zambon, Teva Pharmaceutical Industries, Mylan N.V., Salix Pharmaceuticals, Ferring Pharmaceuticals and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Mesalazine Suppositories market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Mesalazine Suppositories and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Mesalazine Suppositories sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mesalazine Suppositories market size, projected growth trends, production technologies, key applications, and end-use industries.
Mesalazine Suppositories Segment by Company
Zambon
Teva Pharmaceutical Industries
Mylan N.V.
Salix Pharmaceuticals
Ferring Pharmaceuticals
AbbVie
Mesalazine Suppositories Segment by Type
0.25g
0.5g
1g
Mesalazine Suppositories Segment by Application
Hospital
Clinic
Others
Mesalazine Suppositories Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalazine Suppositories market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalazine Suppositories and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalazine Suppositories.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Mesalazine Suppositories market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalazine Suppositories manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mesalazine Suppositories in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Mesalazine Suppositories in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 0.25g
- 0.5g
- 1g
Applications
- Hospital
- Clinic
- Others
Companies covered
- Zambon
- Teva Pharmaceutical Industries
- Mylan N.V.
- Salix Pharmaceuticals
- Ferring Pharmaceuticals
- AbbVie
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Mesalazine Suppositories Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Mesalazine Suppositories Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Mesalazine Suppositories Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Mesalazine Suppositories Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Mesalazine Suppositories Market Dynamics
- 2.1 Mesalazine Suppositories Industry Trends
- 2.2 Mesalazine Suppositories Industry Drivers
- 2.3 Mesalazine Suppositories Industry Opportunities and Challenges
- 2.4 Mesalazine Suppositories Industry Restraints
3 Mesalazine Suppositories Market by Manufacturers
- 3.1 Global Mesalazine Suppositories Revenue by Manufacturers (2021-2026)
- 3.2 Global Mesalazine Suppositories Sales by Manufacturers (2021-2026)
- 3.3 Global Mesalazine Suppositories Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Mesalazine Suppositories Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mesalazine Suppositories Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Mesalazine Suppositories Manufacturers, Product Type & Application
- 3.7 Global Mesalazine Suppositories Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Mesalazine Suppositories Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Mesalazine Suppositories Players Market Share by Revenue in 2025
- 3.8.3 2025 Mesalazine Suppositories Tier 1, Tier 2, and Tier 3
4 Mesalazine Suppositories Market by Type
- 4.1 Mesalazine Suppositories Type Introduction
- 4.1.1 0.25g
- 4.1.2 0.5g
- 4.1.3 1g
- 4.2 Global Mesalazine Suppositories Sales by Type
- 4.2.1 Global Mesalazine Suppositories Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Mesalazine Suppositories Sales by Type (2021-2032)
- 4.2.3 Global Mesalazine Suppositories Sales Market Share by Type (2021-2032)
- 4.3 Global Mesalazine Suppositories Revenue by Type
- 4.3.1 Global Mesalazine Suppositories Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Mesalazine Suppositories Revenue by Type (2021-2032)
- 4.3.3 Global Mesalazine Suppositories Revenue Market Share by Type (2021-2032)
5 Mesalazine Suppositories Market by Application
- 5.1 Mesalazine Suppositories Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Mesalazine Suppositories Sales by Application
- 5.2.1 Global Mesalazine Suppositories Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Mesalazine Suppositories Sales by Application (2021-2032)
- 5.2.3 Global Mesalazine Suppositories Sales Market Share by Application (2021-2032)
- 5.3 Global Mesalazine Suppositories Revenue by Application
- 5.3.1 Global Mesalazine Suppositories Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Mesalazine Suppositories Revenue by Application (2021-2032)
- 5.3.3 Global Mesalazine Suppositories Revenue Market Share by Application (2021-2032)
6 Global Mesalazine Suppositories Sales by Region
- 6.1 Global Mesalazine Suppositories Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mesalazine Suppositories Sales by Region (2021-2032)
- 6.2.1 Global Mesalazine Suppositories Sales by Region (2021-2026)
- 6.2.2 Global Mesalazine Suppositories Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mesalazine Suppositories Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mesalazine Suppositories Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mesalazine Suppositories Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mesalazine Suppositories Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mesalazine Suppositories Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mesalazine Suppositories Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Mesalazine Suppositories Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Mesalazine Suppositories Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Mesalazine Suppositories Revenue by Region
- 7.1 Global Mesalazine Suppositories Revenue by Region
- 7.1.1 Global Mesalazine Suppositories Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Mesalazine Suppositories Revenue by Region (2021-2026)
- 7.1.3 Global Mesalazine Suppositories Revenue by Region (2027-2032)
- 7.1.4 Global Mesalazine Suppositories Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Mesalazine Suppositories Revenue (2021-2032)
- 7.2.2 North America Mesalazine Suppositories Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Mesalazine Suppositories Revenue (2021-2032)
- 7.3.2 Europe Mesalazine Suppositories Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Mesalazine Suppositories Revenue (2021-2032)
- 7.4.2 Asia-Pacific Mesalazine Suppositories Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Mesalazine Suppositories Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Mesalazine Suppositories Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Zambon
- 8.1.1 Zambon Company Information
- 8.1.2 Zambon Business Overview
- 8.1.3 Zambon Mesalazine Suppositories Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Zambon Mesalazine Suppositories Product Portfolio
- 8.1.5 Zambon Recent Developments
- 8.2 Teva Pharmaceutical Industries
- 8.2.1 Teva Pharmaceutical Industries Company Information
- 8.2.2 Teva Pharmaceutical Industries Business Overview
- 8.2.3 Teva Pharmaceutical Industries Mesalazine Suppositories Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Teva Pharmaceutical Industries Mesalazine Suppositories Product Portfolio
- 8.2.5 Teva Pharmaceutical Industries Recent Developments
- 8.3 Mylan N.V.
- 8.3.1 Mylan N.V. Company Information
- 8.3.2 Mylan N.V. Business Overview
- 8.3.3 Mylan N.V. Mesalazine Suppositories Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Mylan N.V. Mesalazine Suppositories Product Portfolio
- 8.3.5 Mylan N.V. Recent Developments
- 8.4 Salix Pharmaceuticals
- 8.4.1 Salix Pharmaceuticals Company Information
- 8.4.2 Salix Pharmaceuticals Business Overview
- 8.4.3 Salix Pharmaceuticals Mesalazine Suppositories Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Salix Pharmaceuticals Mesalazine Suppositories Product Portfolio
- 8.4.5 Salix Pharmaceuticals Recent Developments
- 8.5 Ferring Pharmaceuticals
- 8.5.1 Ferring Pharmaceuticals Company Information
- 8.5.2 Ferring Pharmaceuticals Business Overview
- 8.5.3 Ferring Pharmaceuticals Mesalazine Suppositories Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Ferring Pharmaceuticals Mesalazine Suppositories Product Portfolio
- 8.5.5 Ferring Pharmaceuticals Recent Developments
- 8.6 AbbVie
- 8.6.1 AbbVie Company Information
- 8.6.2 AbbVie Business Overview
- 8.6.3 AbbVie Mesalazine Suppositories Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 AbbVie Mesalazine Suppositories Product Portfolio
- 8.6.5 AbbVie Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Mesalazine Suppositories Value Chain Analysis
- 9.1.1 Mesalazine Suppositories Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Mesalazine Suppositories Production Mode & Process
- 9.2 Mesalazine Suppositories Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mesalazine Suppositories Distributors
- 9.2.3 Mesalazine Suppositories Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst